TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06165562

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PSV
Description: Pressure support ventilation applied from the start of subcutaneous suture until extubation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Manual Assistance
Description: Volume-controlled mode during surgery, with intermittent manual assistance from the end of surgery until extubation.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EEG-Guidance
Description: Extubation criteria based on EEG findings:Zipper opening pattern observed in the spectrogram 95% spectral edge frequency (SEF) ≥ 23 Patient state index (PSI) ≥ 64

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Obey Command
Description: Extubation criteria include obeying commands (eye-opening or handgrip).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Spontaneous Respiration
Description: Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Spontaneous Respiration
Description: Extubation criteria include:~Tidal volume \> 5 ml/kg End-tidal carbon dioxide (ETCO2) \< 45 mmHg Spontaneous respiratory rate (RR) 10 to 20 breaths/min
Study: NCT04231084

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vasodilator testing (Inhaled Nitric Oxide)
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasodilator testing (Inhaled Epoprostenol)
Description: Right heart catheterization with vasodilator testing with each arms' associated agent will be performed
Study: NCT05730387

Intervention type: OTHER
Intervention: Observational only
Description: This is a non-interventional study
Study: NCT05161611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zinc sulfate
Description: 10 mg of oral zinc sulfate will be given to neonates per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 mg of normal saline will be given to neonates per day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Phototherapy
Description: Neonates will be put under phototherapy

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Neonates will be put under phototherapy
Study: NCT05633485

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Animation-Supported Education
Description: Expert support was received for the design and preparation of animation videos.
Study: NCT05070286

Intervention type: BEHAVIORAL
Intervention: Observational Study.
Description: Semi-structured interviews.

Intervention type: BEHAVIORAL
Intervention: Observational Study.
Description: Semi-structured interviews.

Intervention type: BEHAVIORAL
Intervention: Observational Study.
Description: Semi-structured interviews.
Study: NCT05603429

Intervention type: DIAGNOSTIC_TEST
Intervention: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Description: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress

Intervention type: DIAGNOSTIC_TEST
Intervention: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Description: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress

Intervention type: DIAGNOSTIC_TEST
Intervention: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Description: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress

Intervention type: DIAGNOSTIC_TEST
Intervention: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status
Description: Endocan, E-Selectin, TNF-alpha, Total Oxidant and Antioxidant Status measurements for determining Endothelial Damage and Oxidative Stress
Study: NCT06543433

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Skincubator 2
Description: The Skincubator is a small incubator designed to attach to the caregiver's torso without any barrier between the parent's chest and the baby. It creates an environment with the advantages of a standard neonatal incubator, while enabling Skin to Skin contact for extended periods from birth. It has multiple access points, to allow for common nursing procedures. It is anchored safely to the parent's body and secures ventilator and IV tubing. It also includes side ports for the parents to insert their hands to touch their baby.~The investigators will offer the parents in the intervention group the opportunity to perform Skincubator care for as long as they want to each day during the week after enrolment. The investigators will provide the parents with the aids to accomplish this goal: the Skincubator system with a convenient environment, the option for Skincubator surrogates and, where possible, the option for one of the parents to sleep with the baby safely secured in the Skincubator.
Study: NCT05436548

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervisor-employee frequent check-ins to identify and address work stressors
Description: Supervisors will complete three training modules: 1) how and why the check-ins are expected to address burnout; 2) how to demonstrate supportive supervision during the check-ins process, and 3) principle of quality improvement applied to the check-ins

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Usual practice waitlist controls
Description: If the check-ins are successful in reducing burnout, supervisors at the control clinics will be offered the training modules
Study: NCT05721066

Intervention type: DIAGNOSTIC_TEST
Intervention: ClotPro assessment
Description: Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)

Intervention type: DIAGNOSTIC_TEST
Intervention: ClotPro assessment
Description: Point-of-care viscoelastic assessment of the coagulation profile (extrinsic pathway, intrinsic pathway, fibrinogen contribution, tPA stimulated fibrinolysis)

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis
Description: Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)

Intervention type: DIAGNOSTIC_TEST
Intervention: Laboratory analysis
Description: Blood count and standard coagulation tests (INR, aPTT, fibrinogen, D-dimers, antithrombin)

Intervention type: OTHER
Intervention: Interview
Description: Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.

Intervention type: OTHER
Intervention: Interview
Description: Questionnaire from ISS (Istituto Superiore Sanità, the National Health Institute) about the health conditions before the acute COVID-19 infection, the disease (and the hospitalization) details and the eventual health disturbances experienced after the recovery from COVID-19 infection.
Study: NCT06151652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alpha Lipoic Acid 600 MG Oral Tablet
Description: Alpha-lipoic acid (Thiotacid 600 mg ®) at a dose of 600 mg three times daily for one day prior to surgery, followed by Alpha-lipoic acid 600 mg twice daily for 5 days post-surgery plus the standard care.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study: NCT06360913

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: High resolution mass spectrometry
Description: Metabolomics study
Study: NCT05921955

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Optiflow high-flow nasal cannula system
Description: Using the Optiflow high-flow nasal cannula system to supply oxygen for maternal.
Study: NCT06545357

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Acupuncture
Description: To conduct this intervention, we used disposable acupuncture needles with the size of 0.30 x 25 mm to acupuncture at biceps brachii muscle, supraspinatus muscle and deltoid muscles or acupoints on The Yang Ming Channel for 20 minutes, frequency ≤ 20 Hz, intensity from 2- 10mA
Study: NCT05176912

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Reformer Pilates exercises will given for 8 weeks, 3 days in a week
Study: NCT06124131

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for colorectal cancer screening
Description: $50 incentive paid to participant for completion of colorectal cancer screening within 2 months of enrollment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for flu shot
Description: $50 incentive paid to participant for completion of flu shot within 2 months of enrollment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive for flu shot
Description: $50 incentive paid to participant for completion of flu shot within 2 months of enrollment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentive for COVID-19 shot
Description: $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Financial incentive for COVID-19 shot
Description: $50 incentive paid to participant for completion of COVID-19 shot within 2 months of enrollment
Study: NCT06540469

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine Supplementation in Whole Course of Treatment with ATDs
Description: Moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken from ATDs treatment starting until 1 year after ATDs withdrawal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Iodine Supplementation During Maintenance Treatment with ATDs
Description: Iodine restriction (non-iodized salt and low iodine diet) will be demanded at the early course of ATDs treatment, and moderate iodine supplementation (150μg iodine per day, equivalently 7-9g iodized salt per day) will be taken when the ATDs dose is titrated down to a maintenance level until 1 year after ATDs withdrawal.

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Iodine Restriction in Whole Course of Treatment with ATDs
Description: Iodine restriction (non-iodized salt and low iodine diet) will be demanded from ATDs treatment starting until 1 year after ATDs withdrawal.

Intervention type: DRUG
Group type: OTHER
Intervention: anti-Thyroid Drugs
Description: Individualized methimazole (MMI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-Thyroid Drugs
Description: Individualized methimazole (MMI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anti-Thyroid Drugs
Description: Individualized methimazole (MMI)
Study: NCT05239143

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: P-MUC1C-ALLO1 CAR-T cells
Description: P-MUC1C-ALLO1 is an allogeneic CAR-T cell therapy designed to target cancer cells expressing MUC1-C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rimiducid
Description: Rimiducid (safety switch activator) may be administered as indicated.
Study: NCT06117813

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nu.T
Description: Participants receive visual perceptual training using the Nu.T software.

Intervention type: OTHER
Group type: OTHER
Intervention: No-Treatment Control
Description: No-treatment was administered during control period.
Study: NCT06349005

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using Storz VL
Description: Video-assisted intubation technique using Storz VL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using Macintosh laryngoscopy
Description: Traditional intubation technique using Macintosh laryngoscopy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using MacGrath VL
Description: Video-assisted intubation technique using MacGrath VL

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal intubation using EzVision VL
Description: Video-assisted intubation technique using EzVision VL
Study: NCT05536531

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES)
Description: Electrical stimulator (Electrostimulator TRAINFES 6 ADVANCED, Biomedical devices Spa, Santiago, Chile.) to administer NMES
Study: NCT05451446

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: proprietary water
Description: They are randomized to consume a proprietary water product for five-free living days and to drink on the heat stress chamber day.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active comparator
Description: They are randomized to consume a carbohydrate drink for five-free living days and to drink on the heat stress chamber day.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They are randomized to consume water for five-free living days and to drink on the heat stress chamber day.
Study: NCT06540404

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulse traction
Description: The subjects underwent impulse traction of the knee joint in the second degree according to the Kaltenborn concept.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Continuous traction
Description: The subjects underwent continuous traction of the knee joint in the third degree according to the Kaltenborn concept.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham therapy
Description: The therapist did not use traction force, the knee joint was kept in a flexed position of 40 degrees.
Study: NCT04874545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Total intravenous inhalational anesthesia

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Total intravenous inhalational anesthesia
Study: NCT06548191

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-restricted eating
Description: Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Time-restricted eating
Description: Fasting (abstinence from calorie-containing food or drink) during 14 h at night, with no caloric consumption after 8 pm to align with circadian rhythms
Study: NCT05998837

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10mg Tab
Description: Dapagliflozin will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be add on RAAS-i titrated with the aim to reach optimal blood pressure control as defined by European Society of Hypertension (i.e., 120-130/70-80 mmHg) in all subject.~Prior to randomization all the patient with Type 2 Diabetes must have undergone at least 4 weeks of therapy with metformin and/or repaglinide
Study: NCT05797077

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colorectal resection surgery.
Description: Colorectal cancer radical resection combined with liver metastasis resection or ablation.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Colorectal resection surgery.
Description: Colorectal cancer radical resection combined with liver metastasis resection or ablation.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: FOLFOX chemotherapy regimen
Description: Chemotherapy regimens recommended include oxaliplatin-based CapeOx or FOLFOX regimens, or single-agent 5-FU/LV, capecitabine, or combination with targeted therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Maintenance therapy is recommended to be continued with low-toxicity drugs such as 5-FU/LV or capecitabine, and may be combined with targeted therapy. Treatment should be discontinued once ctDNA testing is negative.
Study: NCT04399083

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Caffeine
Description: Caffeine will be administered to each participant following an individualized optimal dosing schedule created by the 2B-Alert app. Individualized caffeine dosing schedules will be created by the 2BAlert app on the smartphone the participant uses to do Smart-PVT tests. Study staff will run the optimization at 1900 on Day 15. The algorithm will recommend caffeine dosing to optimize performance during the Peak Alertness window (e.g. from 0300-0900 on Day 16, 44-50 hours of continuous sleep loss). Doses could be recommended at any hour from 2000 on Day 15 to 0800 on Day 16. HOWEVER, the algorithm will not exceed 800 mg of caffeine across the entire study AND it will not dose more than 300 mg of caffeine at a time. Gum will be chewed for a total of 10 minutes by each participant and then discarded.~As there will be no placebo in this protocol, randomization and blinding procedures are not necessary. IT IS IMPORTANT TO NOTE THAT SOME PARTICIPANTS MAY NOT RECEIVE CAFFEINE AT ALL.
Study: NCT04345666

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Testosterone cypionate
Description: The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: The intervention of this study is to treat patients to either 1) testosterone cypionate or 2) placebo (sterile saline) to determine if there is a difference in recovery times after arthroscopic rotator cuff repair